An interventional study of Progressive Resistance Exercise Training in Polyneuropathy and Charcot Marie Tooth Disease (CMT), sponsored by Universidad de La Frontera. Recruiting at 2 sites in Chile. Open to participants aged 15 Years to 29 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-23.
Sponsored by Universidad de La Frontera · Not applicable, Interventional, and Treatment
The goal of this clinical trial is to compare the effects of an 8-week resistance exercise training program on skeletal muscle quality, functional capacity, and quality of life in young individuals aged 15 to 29 years, with and without Hereditary Sensorimotor Polyneuropathy (HSPN).
The main questions to answer are:
What is the effect of an 8-week resistance exercise training program on skeletal muscle quality, functional capacity, and quality of life in young individuals with and without HSPN?
Will the percentage of improvement after the program be greater in participants with HSPN compared to those without, due to greater baseline alterations?
Researchers will compare the resistance exercise training program with baseline conditions to determine its effectiveness in improving skeletal muscle quality, functional capacity, and quality of life.
Participants will undergo a supervised lower-limb resistance exercise program (3x/week) for 8 weeks. The intervention will include progressive loads from 60% to 80% of 1-Repetition Maximum (1RM), with exercises targeting the major lower limb muscle groups. All participants will complete pre- and post-intervention evaluations, including ultrasound assessment of muscle architecture, functional capacity tests, strength measurements, body composition analysis, and quality of life questionnaires.
Introduction: Hereditary sensorimotor polyneuropathy (HSPN), also known as Charcot-Marie-Tooth disease (CMT), is the most prevalent group of hereditary neuromuscular disorders. It is characterized by muscle distal weakness, muscle atrophy, sensory loss, balance impairments, skeletal deformities and, in some cases, respiratory dysfunction. These impairments lead to reduced muscle quality, functional capacity, and quality of life. Muscle quality encompasses both morphological and functional aspects of skeletal muscle, including muscle architecture, composition, and strength.
Resistance exercise training (RET) has been shown to improve strength, muscle morphology, and functional performance in various populations. However, there is limited evidence on its effectiveness in individuals with HSPN, particularly in young adults. No studies to date have compared the effects of lower-limb-focused RET on muscle quality, functional capacity, and quality of life in young adults with and without HSPN.
Objectives:
The primary objetive of this study will be to assess the change in muscle thickness and echogenicity as markers of muscle quality, evaluated through ultrasonography in the tibialis anterior muscles of the lower limbs of participants undergoing 8 weeks of resistance training
Secondary objectives include:
Materials and Methods: This clinical trial will recruit 22 participants (n=11 with HSPN, n=11 without HSPN), aged 15-29 years. Participants will be assigned to an 8-week supervised lower-limb RET program, performed 3 times per week, with progressive loads from 60% to 80% of one-repetition maximum (1RM). Exercises will target the major lower limb muscle groups and include leg press, knee extension, knee flexion, and ankle dorsiflexion.
Assessments will be conducted pre- and post-intervention, including:
Expected Results: It is hypothesized that 8 weeks of progressive RET will result in greater improvements in muscle quality, functional capacity, and quality of life compared to baseline in both groups, with greater relative improvements expected in participants with HSPN due to lower baseline values. Increases in tibialis anterior thickness and reductions in echogenicity are expected, along with improvements in muscle strength, aerobic capacity, and balance. No serious adverse events are anticipated.
113 studies on the registry are indexed under Charcot-Marie-Tooth Disease; 38 are open to participants now.
This study's planned enrollment of 22 is below the median of 41 across 62 interventional studies indexed under Charcot-Marie-Tooth Disease.
Browse Charcot-Marie-Tooth Disease studies →Universidad de La Frontera is the lead sponsor of 33 studies on the registry; 15 are open to participants now.
Compared within Charcot-Marie-Tooth Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Polyneuropathies. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with Charcot-Marie-Tooth (CMT) will perform an 8-week supervised lower limb Progressive Resistance Exercise Training (RET) program, 3 times per week. Assessments will be conducted pre- and post-intervention to evaluate muscle quality, functional capacity, and quality of life.
Other: Progressive Resistance Exercise Training
Healthy participants (without Charcot Marie Tooth) will perform an 8-week supervised lower limb Progressive Resistance Exercise Training (RET) program, 3 times per week. Assessments will be conducted pre- and post-intervention to evaluate muscle quality, functional capacity, and quality of life.
Other: Progressive Resistance Exercise Training
Progressive Resistance Exercise Training Supervised (RET) focusing on lower limbs. Warm-up (5 min cycling), followed by 5 sets of leg press, leg extension, leg curl, and weighted dorsiflexion. Cool-down with flexibility exercises. Load progression from 60% to 80% of 1Repetition Maximum across 8 weeks. Participants must complete ≥80% of sessions. Evaluators of pre- and post-intervention outcomes will be blinded.
Changes in muscle echogenicity as marker of muscle quality
.Echogenicity of the tibialis anterior muscle in both lower limbs will be assessed using ultrasonography (GE Logiq e BT11, 10-MHz linear transducer) by an experienced examiner. Participants will be seated with knees flexed and feet supported; the head of the fibula and lateral malleolus will serve as reference points. Echointensity will be analyzed in ImageJ from transverse images, excluding bone and fascia, and expressed as 0-255 A.U.
Time frame: The evaluation will be conducted twice, before and after the 8-week intervention: the first, 2 days after signing the informed consent, and the second, 2 days after completing the treatment.
Changes in muscle thickness as marker of muscle quality
Muscle thickness of the tibialis anterior muscle in both lower limbs will be assessed using ultrasonography (GE Logiq e BT11, 10-MHz linear transducer). Participants will be seated with knees flexed and feet supported; the head of the fibula and the lateral malleolus will serve as anatomical reference points. Muscle thickness will be defined as the orthogonal distance between the superficial and deep aponeuroses, measured at the midpoint of the transverse ultrasonographic image expressed in millimeters (mm).
Time frame: The evaluation will be conducted twice, before and after the 8-week intervention: the first, 2 days after signing the informed consent, and the second, 2 days after completing the treatment.
Changes in muscle architecture through ultrasonographic evaluation (fascicle length and pennation angle)
Measurements will be performed on the tibialis anterior muscle of both lower limbs using ultrasonography (GE Logiq e BT11, General Electric, Boston, MA, USA) with a 10-MHz linear transducer by an evaluator experienced in muscle ultrasound analysis. For the assessment, participants will be positioned in a seated posture with knees flexed in neutral position and feet supported without footwear. The head of the fibula and the center of the lateral malleolus will be used as anatomical landmarks, where the total length will be measured and divided into three portions. Measurements will be obtained with the transducer placed transversely on the muscle belly located in the upper third of the distance measured between the two aforementioned bony landmarks. The analysis of muscle architecture will be performed using the public-domain software NIH ImageJ. This quantification will also be carried out by a blinded evaluator.
Time frame: The evaluation will be conducted twice, before and after the 8-week intervention: the first, 2 days after signing the informed consent, and the second, 2 days after completing the treatment.
Serum creatine kinase concentration as a biomarker of muscle quality.
Blood samples will be collected in the morning after a 12-hour fasting period from a superficial vein in the cubital fossa. Samples will be obtained on the first evaluation day (1 week before starting training) and 48 hours after the final training session. They will be drawn into serum-separator tubes without anticoagulant, centrifuged at 2500 rpm for 15 minutes, and the resulting serum will be aliquoted into microtubes and stored at -80 °C for subsequent analysis of Creatine Kinase levels.
Time frame: The evaluation will be conducted twice, before and after the 8-week intervention: the first, 2 days after signing the informed consent, and the second, 2 days after completing the treatment.
Changes in total body mass
Total and regional lean body mass will be assessed by bioelectrical impedance analysis (HBF-514C, Omron©, Japan) after overnight fasting, with participants standing. Lean body mass will be expressed in kilograms (kg) and as a percentage of total body mass (%).
Time frame: The evaluation will be conducted twice, before and after the 8-week intervention: the first, 4 days after signing the informed consent, and the second, 4 days after completing the treatment.
Variation in anthropometric measurements
anthropometric measurements will include body weight measured in kilograms (Kg), height, waist to hip, chest, thigh, and calf circumferences, as well as knee height and leg length mesuared in milimiters (mm). Weight and height will be obtained with a SECA® platform scale and stadiometer (Madison, WI, USA), while circumferences will be measured with a retractable SECA® measuring tape at standardized anatomical landmarks. Weight and height will be combined to report BMI in kg/m\^2
Time frame: The evaluation will be conducted twice, before and after the 8-week intervention: the first, 4 days after signing the informed consent, and the second, 4 days after completing the treatment.
Changes in aerobic capacity
Oxygen consumption (VO₂) will be measured during the 6-Minute Walk Test (6MWT) using a portable metabolic analyzer (PNOE, ENDO Medical, Palo Alto, CA). Breath-by-breath respiratory gas exchange kinetics will be recorded, while heart rate will be continuously monitored with an ECG-activated POLAR® chest strap (Finland). VO₂, VCO₂ and tidal volume, be assessed via a face mask equipped with a flow sensor and gas analyzer with minimal dead space (\<70 ml). Data will be transmitted in real time to a laptop through a harness-secured system, enabling continuous monitoring throughout the tests.
Time frame: The evaluation will be conducted twice, before and after the 8-week intervention: the first, 4 days after signing the informed consent, and the second, 4days after completing the treatment.
Changes in respiratory muscle strength
Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) will be assessed using a portable handheld spirometer (MicroRPM, Micro Medical/CareFusion, Kent, UK). Measured in centimeters of water (cmH₂O)
Time frame: The evaluation will be conducted twice, before and after the 8-week intervention: the first, 4 days after signing the informed consent, and the second, 4 days after completing the treatment.
Changes in maximal handgrip strength
Handgrip strength will be measured using a JAMAR dynamometer (model BK-7498, Fred Sammons, Inc., Burr Ridge, IL) for both upper limbs. Each hand will be tested three times with a 30-second rest between trials, and the highest value from the six attempts will be recorded
Time frame: The evaluation will be conducted twice, before and after the 8-week intervention: the first, 2 days after signing the informed consent, and the second, 2 days after completing the treatment.
Changes in overall lower-limb strength
This will be assessed using the Sit-to-Stand Test (STST). The participant will sit on a chair with arms crossed over the chest and, upon the command 'ready, go,' will stand up and sit down as many times as possible within 1 minute. The total number of repetitions will be recorded.
Time frame: The evaluation will be conducted twice, before and after the 8-week intervention: the first, 2 days after signing the informed consent, and the second, 2 days after completing the treatment.
Changes in overall upper-limb strength
Upper-limb strength will be assessed with the 30-s Arm Curl Test using a dumbbell (2.5 kg for women, 3.5 kg for men), recording the number of full elbow flexion-extension repetitions completed in 30 seconds
Time frame: The evaluation will be conducted twice, before and after the 8-week intervention: the first, 2 days after signing the informed consent, and the second, 2 days after completing the treatment.
Changes in maximal voluntary isometric strength
Maximal voluntary isometric strength of the ankle dorsiflexors will be assessed bilaterally using a force transducer (Load Cell -500 lb, Sensortronics, USA). After a 5-minute ankle mobility warm-up, participants will be seated with the trunk supported, hip at 90°, knee extended, and foot perpendicular to the transducer. The best of three maximal dorsiflexion trials, performed at high speed with verbal encouragement, will be recorded.
Time frame: The evaluation will be conducted twice, before and after the 8-week intervention: the first, 2 days after signing the informed consent, and the second, 2 days after completing the treatment.
Changes in functional ankle muscle strength
This will be assessed using the Heel Raise Test. The participant will stand facing a platform or step, keeping the body upright and feet parallel with the forefoot placed on the platform edge, while supporting themselves on the wall with both hands. They will be instructed to rise onto the toes as many times as possible within 30 seconds, and the total number of repetitions will be recorded.
Time frame: The evaluation will be conducted twice, before and after the 8-week intervention: the first, 2 days after signing the informed consent, and the second, 2 days after completing the treatment.
Changes maximal lower-limb muscle strength
Maximal strength will be determined through a one-repetition maximum (1RM) test for the lower limbs using leg press and knee extension machines (TuffStuff Fitness International), as well as free weights for ankle dorsiflexion and plantarflexion exercises
Time frame: The evaluation will be conducted twice, before and after the 8-week intervention: the first, 2 days after signing the informed consent, and the second, 2 days after completing the treatment.
Changes in balance and gait performance
Blance and Gait will be assessed with the Tinetti Performance-Oriented Mobility Assessment (POMA), which includes 22 items divided into gait (12 points) and balance (16 points), for a total of 28 points. Scores of 19-24 indicate minimal fall risk, while scores \<19 indicate high fall risk.
Time frame: The evaluation will be conducted twice, before and after the 8-week intervention: the first, 4 days after signing the informed consent, and the second, 4 days after completing the treatment.
Changes in health-related quality of life (HRQoL)
Health-related quality of life will be assessed with the SF-36, a validated 36-item questionnaire covering 8 domains and 2 summary components (Physical Component Summary and Mental Component Summary). Scores range from 0 to 100%, with higher scores indicating better quality of life.
Time frame: The evaluation will be conducted twice, before and after the 8-week intervention: the first, 4 days after signing the informed consent, and the second, 4 days after completing the treatment.
Changes physical activity levels
The International Physical Activity Questionnaire (IPAQ) assesses physical activity levels across four domains: work, domestic, transport, and leisure time. Physical activity is expressed both continuously, in metabolic equivalent (MET)-minutes/week, and categorically, classifying activity level as low, moderate, or high. METs provide a way to estimate energy expenditure as multiples of basal metabolic rate, and the unit used, MET-minutes, is calculated by multiplying the MET value of an activity by the minutes performed per day or per week. In this study, results will be expressed in MET-minutes/week.
Time frame: The evaluation will be conducted twice, before and after the 8-week intervention: the first, 4 days after signing the informed consent, and the second, 4 days after completing the treatment.
Not enrolling at this site.
Plan to share: No — individual participant data will not be shared due to ethical restrictions and the risk of participant re-identification, as the informed consent did not include provisions for public data sharing.
Started Sep 2025 (actual). Primary completion is estimated for Jul 2026, 10 months after the start.
Of 38 interventional studies with no phase under Charcot-Marie-Tooth Disease, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 67. This study's planned 10 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidad de La Frontera